Literature DB >> 3997075

Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: its relationship to hepatic fibrosis, activity of the disease and iron overload.

M Colombo, G Annoni, M F Donato, D Conte, D Martines, M G Zaramella, P A Bianchi, A Piperno, C Tiribelli.   

Abstract

To assess the value of type III procollagen peptide (sPIIIP) as a marker of hepatic fibrosis, sera from 73 patients with alcohol-related liver disease and 30 patients with idiopathic hemochromatosis (IHC) were studied by a specific radioimmunoassay. sPIIIP was increased in 87% of 30 patients with cirrhosis, in 16% of 32 with steatofibrosis but in none of 11 with steatosis. There was a significant correlation with histologic hepatocellular necroinflammation (r = 0.42, p less than 0.01), but not with hepatic fibrosis. sPIIP was increased in 33% of 30 patients with IHC, whether or not they had cirrhosis or fibrosis, and whatever the level of iron overload or the extent of the hepatic deterioration. IHC patients with increased levels of sPIIIP had a higher prevalence of superimposed hepatic damage than did those with normal procollagen levels (p less than 0.05). Our findings, therefore, weaken the diagnostic value of sPIIIP as an index of connective tissue deposition in the liver, and suggest that, at least in alcohol-related liver disease and IHC, hepatocellular necroinflammation influences the results.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3997075     DOI: 10.1002/hep.1840050322

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Type I and type III procollagen peptides during hepatic fibrogenesis. An immunohistochemical and ELISA serum study in the CCl4 rat model.

Authors:  B H Davis; J A Madri
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

2.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

3.  An immunohistochemical and serum ELISA study of type I and III procollagen aminopropeptides in primary biliary cirrhosis.

Authors:  B H Davis; J A Madri
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

4.  Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.

Authors:  D Y Lin; C M Chu; I S Sheen; Y F Liaw
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

5.  Assessment of the fibrogenetic activity in chronic pancreatitis. The role of circulating levels of extracellular matrix components.

Authors:  J E Domínguez-Muñoz; G Manes; M Büchler; P Malfertheiner
Journal:  Int J Pancreatol       Date:  1993-12

6.  Non-invasive methods for liver fibrosis prediction in hemochromatosis: One step beyond.

Authors:  Agustin Castiella; Eva Zapata; José M Alústiza
Journal:  World J Hepatol       Date:  2010-07-27

7.  Serum laminin--its concentration increases with portal hypertension in cirrhotic liver disease.

Authors:  A M Gressner; W Tittor
Journal:  Klin Wochenschr       Date:  1986-12-01

Review 8.  Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids.

Authors:  Tom Vanden Berghe; Eric Hoste
Journal:  Cell Death Differ       Date:  2018-09-10       Impact factor: 15.828

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.